Investment Thesis
Escalon Medical is a distressed company with deteriorating fundamentals, burning cash at an unsustainable rate while generating minimal revenue growth. Negative operating cash flow of -432.4K, combined with persistent operating losses and a weak equity base of only 1.8M, indicates the company is in financial distress with limited runway.
Strengths
- Low leverage with debt-to-equity of only 0.01x provides some financial flexibility
- Current ratio of 1.65x indicates adequate short-term liquidity to cover immediate obligations
- Established presence in electromedical apparatus sector with existing revenue base of 6.3M
Risks
- Negative free cash flow of -436.8K annually indicates unsustainable cash burn with only 337.4K cash available
- Operating losses of -104.0K and net losses of -142.2K show inability to generate profitability at current scale
- Minimal revenue growth of 0.5% YoY combined with negative operating margins suggests business model deterioration or lack of market demand
- Cash runway appears critically limited; at current burn rate, available cash depleted within months
- No insider buying activity in last 90 days, suggesting lack of management confidence
Key Metrics to Watch
- Operating cash flow - must return to positive territory
- Revenue growth rate - currently stagnant; needs 10%+ growth to stabilize
- Cash balance and runway - monitor for financing needs or dilution events
- Path to operating profitability - critical for survival
Financial Metrics
Revenue
6.3M
Net Income
-142.2K
EPS (Diluted)
$-0.02
Free Cash Flow
-436.8K
Total Assets
4.7M
Cash
337.4K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1.7%
Net Margin
-2.3%
ROE
-8.0%
ROA
-3.0%
FCF Margin
-7.0%
Balance Sheet & Liquidity
Current Ratio
1.65x
Quick Ratio
1.06x
Debt/Equity
0.01x
Debt/Assets
68.4%
Interest Coverage
-7.07x
Long-term Debt
18.9K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T12:22:11.048644 |
Data as of: 2026-06-30 |
Powered by Claude AI